Unknown

Dataset Information

0

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.


ABSTRACT: Programmed cell death ligand 1 (PD-L1) is an immunomodulatory molecule expressed by antigen-presenting cells and select tumors that engages receptors on T cells to inhibit T-cell immunity. Immunotherapies targeting the PD-1/PD-L1 pathway have shown durable antitumor effects in a subset of patients with solid tumors. PD-L1 can be expressed by Reed-Sternberg cells comprising classical Hodgkin lymphoma (CHL) and by malignant B cells comprising EBV-positive posttransplant lymphoproliferative disorders (PTLD). We sought to determine whether the expression of PD-L1 represents a general strategy of immune evasion among aggressive B-cell lymphomas and virus- and immunodeficiency-associated tumors.Using novel antibodies and formalin-fixed, paraffin-embedded (FFPE) tissue biopsies, we examined 237 primary tumors for expression of PD-L1.Robust PD-L1 protein expression was found in the majority of nodular sclerosis and mixed cellularity CHL, primary mediastinal large B-cell lymphoma, T-cell/histiocyte-rich B-cell lymphoma, EBV-positive and -negative PTLD, and EBV-associated diffuse large B-cell lymphoma (DLBCL), plasmablastic lymphoma, extranodal NK/T-cell lymphoma, nasopharyngeal carcinoma, and HHV8-associated primary effusion lymphoma. Within these tumors, PD-L1 was highly expressed by malignant cells and tumor-infiltrating macrophages. In contrast, neither the malignant nor the nonmalignant cells comprising nodular lymphocyte-predominant Hodgkin lymphoma, DLBCL-not otherwise specified, Burkitt lymphoma, and HHV8-associated Kaposi sarcoma expressed detectable PD-L1.Certain aggressive B-cell lymphomas and virus- and immunodeficiency-associated malignancies associated with an ineffective T-cell immune response express PD-L1 on tumor cells and infiltrating macrophages. These results identify a group of neoplasms that should be considered for PD-1/PD-L1-directed therapies, and validate methods to detect PD-L1 in FFPE tissue biopsies.

SUBMITTER: Chen BJ 

PROVIDER: S-EPMC4102335 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.

Chen Benjamin J BJ   Chapuy Bjoern B   Ouyang Jing J   Sun Heather H HH   Roemer Margaretha G M MG   Xu Mina L ML   Yu Hongbo H   Fletcher Christopher D M CD   Freeman Gordon J GJ   Shipp Margaret A MA   Rodig Scott J SJ  

Clinical cancer research : an official journal of the American Association for Cancer Research 20130514 13


<h4>Purpose</h4>Programmed cell death ligand 1 (PD-L1) is an immunomodulatory molecule expressed by antigen-presenting cells and select tumors that engages receptors on T cells to inhibit T-cell immunity. Immunotherapies targeting the PD-1/PD-L1 pathway have shown durable antitumor effects in a subset of patients with solid tumors. PD-L1 can be expressed by Reed-Sternberg cells comprising classical Hodgkin lymphoma (CHL) and by malignant B cells comprising EBV-positive posttransplant lymphoproli  ...[more]

Similar Datasets

| S-EPMC5115714 | biostudies-literature
| S-EPMC5902875 | biostudies-literature
| S-EPMC6327052 | biostudies-literature
| S-EPMC8207995 | biostudies-literature
| S-EPMC7924378 | biostudies-literature
| S-EPMC6475614 | biostudies-literature
| S-EPMC5651530 | biostudies-literature
| S-EPMC9313053 | biostudies-literature
| S-EPMC3925108 | biostudies-literature
| S-EPMC8244904 | biostudies-literature